Forty Seven (NASDAQ: FTSV) is one of 554 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Forty Seven to similar companies based on the strength of its analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Insider and Institutional Ownership
43.7% of Forty Seven shares are held by institutional investors. Comparatively, 45.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 37.4% of Forty Seven shares are held by insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Forty Seven and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Forty Seven Competitors||-1,532.25%||-828.72%||-28.02%|
Valuation and Earnings
This table compares Forty Seven and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Forty Seven||N/A||-$70.37 million||-4.22|
|Forty Seven Competitors||$2.13 billion||$224.95 million||-3.88|
Forty Seven’s peers have higher revenue and earnings than Forty Seven. Forty Seven is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings for Forty Seven and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Forty Seven Competitors||4719||13372||28142||1016||2.54|
Forty Seven presently has a consensus target price of $27.71, suggesting a potential upside of 75.07%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.73%. Given Forty Seven’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Forty Seven is more favorable than its peers.
Forty Seven Company Profile
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.